1 – 15 of 43
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Long-term outcomes of vedolizumab in inflammatory bowel disease : the Swedish prospective multicentre SVEAH extension study
(
- Contribution to journal › Article
-
Mark
Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE) : a multicentre, open-label, randomised controlled trial
(
- Contribution to journal › Article
- 2021
-
Mark
Clinical effectiveness of golimumab in ulcerative colitis : a prospective multicentre study based on the Swedish IBD Quality Register, SWIBREG
(
- Contribution to journal › Article
-
Mark
Real-world effectiveness of vedolizumab in inflammatory bowel disease : week 52 results from the Swedish prospective multicentre SVEAH study
(
- Contribution to journal › Article
- 2020
-
Mark
Short and long-term efficacy of adalimumab in ulcerative colitis : a real-life study
(
- Contribution to journal › Article
- 2019
-
Mark
The Cost-effectiveness of Biological Therapy Cycles in the Management of Crohn's Disease
(
- Contribution to journal › Article
-
Mark
Alkaliskt sfingomyelinas, en antiinflamatorisk faktor som kan motverka colit och colorektal cancer
(
- Contribution to journal › Published meeting abstract
- 2018
-
Mark
Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease
(
- Contribution to journal › Article
- 2017
-
Mark
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
(
- Contribution to journal › Article
-
Mark
Long-term effectiveness of vedolizumab in inflammatory bowel disease : a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)
(
- Contribution to journal › Article
- 2016
-
Mark
Introduktion av biosimilarer kräver noggrann övervakning.
(
- Contribution to journal › Article
-
Mark
Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial.
(
- Contribution to journal › Article
- 2015
-
Mark
Enhanced colonic tumorigenesis in alkaline sphingomyelinase (NPP7) knockout mice.
(
- Contribution to journal › Article
- 2014
-
Mark
Changes of activity and isoforms of alkaline sphingomyelinase (nucleotide pyrophosphatase phosphodiesterase 7) in bile from patients undergoing endoscopic retrograde cholangiopancreatography.
(
- Contribution to journal › Article
-
Mark
Alkaline sphingomyelinase (NPP7) promotes cholesterol absorption by affecting sphingomyelin levels in the gut. A study with NPP7 knockout mice.
(
- Contribution to journal › Article